Have a feature idea you'd love to see implemented?
Let us know!
AVIR Atea Pharmaceuticals Inc
Price (delayed)
$3.25
Market cap
$274.5M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.07
Enterprise value
$177.88M
Atea is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing therapies to address the unmet medical needs of patients with life-threatening viral diseases. Leveraging its deep understanding
Highlights
The debt has declined by 29% year-on-year and by 9% since the previous quarter
Atea Pharmaceuticals's quick ratio has decreased by 39% YoY
Atea Pharmaceuticals's net income has decreased by 33% YoY
Key stats
What are the main financial stats of AVIR
Market
Valuations
Earnings
Shares outstanding
84.46M
Market cap
$274.5M
Enterprise value
$177.88M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.6
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$172.96M
EBITDA
-$172.54M
Free cash flow
-$126.94M
Per share
Balance sheet
Liquidity
EPS
-$2.07
Free cash flow per share
-$1.5
Book value per share
$5.43
Revenue per share
$0
TBVPS
$5.82
Total assets
$490.96M
Total liabilities
$32.44M
Debt
$1.84M
Equity
$458.52M
Working capital
$461.72M
Debt to equity
0
Current ratio
19.33
Quick ratio
19.17
Net debt/EBITDA
0.56
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-32.4%
Return on equity
-34.9%
Return on invested capital
-49.9%
Return on capital employed
-37.1%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AVIR stock price
How has the Atea Pharmaceuticals stock price performed over time
Intraday
2.85%
1 week
-1.81%
1 month
-9.47%
1 year
13.24%
YTD
6.56%
QTD
-2.99%
Financial performance
How have Atea Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$200.5M
Net income
-$174.01M
Gross margin
N/A
Net margin
N/A
Atea Pharmaceuticals's net income has decreased by 33% YoY
The operating income is down by 27% YoY
Growth
What is Atea Pharmaceuticals's growth rate over time
Valuation
What is Atea Pharmaceuticals stock price valuation
P/E
N/A
P/B
0.6
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Atea Pharmaceuticals's EPS has decreased by 31% YoY
AVIR's P/B is 68% lower than its 5-year quarterly average of 1.9
The company's equity fell by 21% YoY and by 3.8% QoQ
Efficiency
How efficient is Atea Pharmaceuticals business performance
AVIR's return on invested capital has dropped by 69% year-on-year and by 4.8% since the previous quarter
The company's return on equity has shrunk by 62% YoY and by 5% QoQ
The ROA has shrunk by 57% YoY and by 4.2% QoQ
Dividends
What is AVIR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AVIR.
Financial health
How did Atea Pharmaceuticals financials performed over time
The current ratio has declined by 39% year-on-year
Atea Pharmaceuticals's quick ratio has decreased by 39% YoY
The debt is 100% smaller than the equity
The debt has declined by 29% year-on-year and by 9% since the previous quarter
The company's equity fell by 21% YoY and by 3.8% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.